Bambusa Therapeutics debuted after an IPO that raised $169 million to support its bispecific antibody pipeline, with management positioning the program as an attempt to address limitations of currently available monoclonal antibodies. The company framed the cash as runway for further development across its immunology portfolio. The offering comes alongside another Nasdaq debut, Aspen Neuroscience, as the biotech market continues to test risk appetite in new listings. Bambusa’s strategy centers on bispecific formats designed to deliver differentiating performance versus standard antibody approaches. Investors will now focus on how Bambusa uses the funding to advance lead candidates into clinical proof points and whether its preclinical differentiation translates into durable clinical efficacy and safety.